The Effect of Combination of Sevelamer Carbonate and Hemodialysis on Patients with Renal Osteodystrophy after Uremia
Objective:To observe and explore the effect of hemodialysis combined with Sevelamer Carbonate in the clinical treatment of patients with renal osteodystrophy after uremia and the effect on on fibroblast growth factor 23(FGF-23)and bone morphogenetic protein 7(BMP-7).Method:From January 2022 to January 2023,Nansha Hospital of Guangzhou First People's Hospital received 72 patients with renal osteodystrophy after uremia were selected,and divided to the control group(n=36)and the combined group(n=36)by random number table method.The control group received hemodialysis treatment,and the combined group was treated with Sevelamer Carbonate on the basis of hemodialysis.Clinical efficacy,bone alkaline phosphatase(BAP),FGF-23,BMP-7,parathyroid hormone(PTH),C reactive protein(CRP),β2 microglobulin(β2-MG),osteocalcin(OCN)and adverse reactions of two groups were compared.Result:The total clinical efficiency rate of combination group was 91.67%,higher than 72.22%of control group,the difference was statistically significant(P<0.05).Before treatment,there were no differences in the BAP,FGF-23,BMP-7,PTH,CRP,β2-MG and OCN between the two groups(P>0.05);after treatment,BMP-7 in the combined group was higher than that in the control group,while BAP,FGF-23,PTH,CRP,β2-MG and OCN were lower than those in the control group(P<0.05).The incidence of adverse reaction on bloating,diarrhea,nausea and retching was 11.11%in the combined group and 16.67%in the control group,the difference was not statistically significant(P>0.05).Conclusion:The combination of Sevelamer Carbonate in patients with renal osteodystrophy after uremia during hemodialysis has a definite effect,which can regulate bone metabolism,improve renal function,reduce micro-inflammatory reaction,high safety,patient tolerance.
UremiaRenal osteodystrophyHemodialysisSevelamer CarbonateFibroblast growth factor 23Bone morphogenetic protein 7
万方数据
维普
